

Circulating microRNAs in endometriosis

Victoria Nisenblat

The Robinson Institute
Research Centre for Reproductive Health,
Discipline of Obstetrics and Gynaecology,
University of Adelaide, Adelaide,
Australia

A thesis submitted to the University of Adelaide in fulfilment of the
requirements for admission to the degree Doctor of Philosophy

July 2013



TABLE OF CONTENTS

TABLE OF CONTENTS	I
ABSTRACT	VI
DECLARATION	VIII
ACKNOWLEDGMENTS	IX
PUBLICATIONS ARISING FROM THIS THESIS	XI
COMMERCIAL POTENTIAL ARISING FROM THIS THESIS	XI
ABSTRACTS ARISING FROM THIS THESIS	XII
LIST OF FIGURES	XIII
LIST OF TABLES	XVI
ABBREVIATIONS	XIX
Chapter 1 Introduction	1
1.1 Structure of the thesis	2
1.2 Background to the study	4
1.2.1 The enigma known as endometriosis	4
1.2.2 MiRNAs – small molecules with a huge potential	19
1.3 The need for the study	28
1.4 Hypotheses and objectives	28
Chapter 2 Experimental strategies for circulating miRNA research	31
2.1 Introduction	32
2.2 Quantification of circulating miRNAs	32

2.2.1	Pre-analytical variables and sample preparation	32
2.2.2	MiRNA extraction	35
2.2.3	RNA concentration and quality determination	38
2.2.4	Detection of miRNA expression	40
2.3	Guidelines for publication of the expression profiling data	59
2.4	Summary points	60
Chapter 3	<i>Materials and Methods</i>	63
1.1	Establishment of tissue bank (blood and endometrial tissue samples)	64
3.1.1	Recruitment of participants	64
3.1.2	Sample collection and processing	65
3.2	Optimization of RNA isolation from plasma	66
3.2.1	Plasma to Trisol ratio, plasma dilution, plasma volume	66
3.2.2	Spike- in synthetic miRNAs	68
3.2.3	Inter- and intra-assay variability and use of carrier for small RNA	70
3.2.4	Intra-operator variability	71
3.2.5	Assessment of miRNA quality and quantity	72
3.3	The protocol of RNA isolation from plasma, established in our laboratory	74
3.4	MiRNA extraction from endometrial tissue	75
3.4.1	MiRNA extraction	75
3.4.2	MiRNA quantification and quality control	76
3.5	MiRNA profiling in plasma	76
3.5.1	TaqMan Low density Human miRNA RT-PCR arrays	77
3.5.2	Singleplex qRT-PCR	81
3.6	MiRNA profiling in endometrial tissue	84
3.6.1	MiRNA microarray and analysis	84
3.7	Statistical analysis	85

3.7.1	Demographic characteristics _____	85
3.7.2	TLDA miRNA experiment in plasma _____	85
3.7.3	Affymetrix hybridisation miRNA microarray in endometrial tissue _____	86
3.7.4	Heat maps and Venn diagrams _____	87
3.7.5	qRT-PCR experiment _____	87
3.7.6	Subgroup analyses (study presented in Chapter 7) _____	87
3.7.7	Diagnostic performance of plasma miRNAs _____	88
3.8	Identification of predicted miRNA targets and in silico functional analysis _____	88
3.9	Strategy for conducting the diagnostic accuracy study _____	90
<i>Chapter 4 Expression profile of plasma miRNAs across the menstrual cycle in</i>		
<i>women with and without endometriosis _____</i>		
4.1	Introduction _____	96
4.2	Materials and Methods _____	96
4.2.1	Study participants _____	96
4.2.2	Blood collection and miRNA extraction _____	97
4.2.3	MiRNA profiling _____	97
4.2.4	Identification of predicted miRNA targets and <i>in silico</i> functional analysis _____	97
4.3	Results _____	97
4.3.1	Study participants _____	97
4.3.2	Performance of the miRNA TLDA _____	98
4.3.3	Expression of the miRNAs across the menstrual cycle _____	101
4.3.4	Differential expression of circulating miRNAs in endometriosis _____	102
4.3.5	Correlation of plasma miRNA profile in endometriosis with previously published data on miRNA signatures in endometrial tissue _____	106
4.3.6	Validation of the array results with qRT-PCR analysis of miRNA expression _____	108
4.3.7	The role of the circulating miRNAs in endometriosis _____	108
4.4	Discussion _____	113

4.4.1	Influence of the menstrual cycle on expression of circulating miRNAs _____	113
4.4.2	The plasma miRNA profile in endometriosis _____	115
4.4.3	Functional involvement of dysregulated plasma miRNAs in endometriosis _____	116
4.4.4	Limitations _____	119
4.5	Conclusions _____	119
Chapter 5 <i>Insight on the function of the dysregulated circulating miRNAs</i> _____		121
5.1	Introduction _____	122
5.2	Materials and methods _____	122
5.3	Results _____	122
5.3.1	The experimentally validated functions and inter-relationships of the circulating miRNAs	122
5.3.2	Review of the role of circulating miRNAs in human disease _____	124
5.4	Conclusions _____	133
Chapter 6 <i>MiRNA expression profile in eutopic endometrium in endometriosis</i> _		135
6.1	Introduction _____	136
6.2	Materials and Methods _____	137
6.2.1	Study Participants _____	137
6.2.2	Tissue collection, RNA extraction and sample quality control _____	138
6.2.3	MiRNA profiling _____	139
6.3	Results _____	139
6.3.1	Study Participants _____	139
6.3.2	Summary on QC of the microarray data _____	140
6.3.3	Differentially expressed miRNAs _____	142
6.4	Discussion _____	148
6.5	Limitations _____	152
6.6	Conclusions _____	152

Chapter 7	<i>Plasma miRNAs as a non-invasive diagnostic tool for endometriosis</i>	155
7.1	Introduction	156
7.2	Materials and Methods	157
7.2.1	Study design	157
7.2.2	Study participants	157
7.2.3	Processing of the samples and miRNA profiling	158
7.2.4	Selection of targets to explore for a diagnostic test	159
7.3	Results	159
7.3.1	Phase I - Marker discovery	159
7.3.2	Phases II-III – Marker selection and large scale validation	161
7.4	Discussion	181
7.5	Limitations	187
7.6	Conclusions	188
Chapter 8	<i>General discussion and conclusions</i>	191
8.1	Introduction	192
8.2	Quantification of circulating miRNA and approach to the data analysis	193
8.3	Influence of the menstrual cycle on expression of circulating miRNAs	194
8.4	Plasma miRNA profile in endometriosis	194
8.5	Functional involvement of dysregulated plasma miRNAs in endometriosis	195
8.6	MiRNA expression in eutopic endometrium in endometriosis	196
8.7	Plasma miRNAs as diagnostic markers for endometriosis	197
8.8	Future perspectives	198
Chapter 9	<i>References</i>	201

ABSTRACT

Endometriosis is defined as the presence of endometrial tissue outside the uterus and is the leading cause of disability in reproductive-age women. The pathogenesis of endometriosis remains unclear and no blood test is available for early diagnosis of the disease. MicroRNAs (miRNAs) are endogenous small ribonucleic acids (RNAs) that have important gene-regulatory roles via posttranscriptional suppression of target genes. The biological importance of miRNAs, initially demonstrated in cancer, has more recently been confirmed in other diseases. In light of the sustained presence of miRNAs in the circulation and given the emerging evidence on aberrant miRNA expression in endometriotic tissue, we hypothesized that endometriosis is associated with unique plasma miRNA signatures that have diagnostic potential and possibly contribute to disease pathogenesis.

In order to test this hypothesis, we established a procedure to measure plasma miRNAs and created a tissue bank of prospectively collected blood and eutopic endometrium samples. Next, by using qRT-PCR-based arrays we screened the plasma of a small set of women (n = 16) with or without endometriosis for miRNA content at 3 different phases of the menstrual cycle. We demonstrated that plasma miRNAs do not fluctuate across the cycle and identified 12 plasma miRNAs that are differentially abundant in endometriosis. In silico functional analyses revealed that these miRNAs and their predicted targets have functional relevance in endometriosis, being involved in molecular pathways known to be associated with the disease.

Using a microarray methodology, we profiled miRNAs in eutopic endometrium from women with and without endometriosis. We demonstrated no correlation between dysregulated miRNAs in endometrium and plasma, suggesting that the differentially abundant circulating miRNAs are not released from the endometrium. Mir-551a and mir-148a* were significantly dysregulated in the endometrium from women with endometriosis, and thus are putative diagnostic markers and therapeutic targets. We also identified differences in miRNA expression between endometriosis-free women with and without pelvic pain, suggesting that pelvic pain might independently modify the endometrial miRNA profile.

Finally, we assessed the value of plasma miRNAs as molecular markers for endometriosis in a prospective diagnostic study in a larger cohort (n = 68) of symptomatic women by using singleplex qRT-PCR. The diagnostic accuracy of circulating miRNAs for patients with

endometriosis was assessed with a predictive algorithm incorporating miRNA expression levels and clinical parameters. A model that included mir-155, mir-574-3p, mir-133a and mir-30c, history of infertility and previous miscarriages demonstrated an accuracy of 84.1% with 93.5% sensitivity, 58.8% specificity and AUC = 0.831.

This thesis presents potential novel biomarkers for early detection of endometriosis, laying the ground work for future efforts to develop blood-based biomarkers for this disease. An accurate non-invasive test would reduce the need for a surgical diagnosis, would be more accessible to women, and is likely to lead to an earlier diagnosis and treatment of endometriosis. Our results need to be confirmed in larger independent patient groups in different populations. In addition, this work raises the possibility that plasma miRNAs may provoke some of the adverse health epiphenomenon associated with endometriosis, which potentially could be altered by therapeutic manipulations of endometriosis-associated plasma miRNAs. Future studies and broader miRNA profiling may elucidate a relationship between miRNAs, endometriotic disease and its severity.

DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma at any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australian Digital Thesis Program and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Victoria Nisenblat

July 2013

ACKNOWLEDGMENTS

It is a pleasure to thank the people without whom this thesis would not have been possible. First and foremost, I would like to thank my supervisors Dr Louise Hull for her able guidance, constructive criticism, timely motivation and mentoring, Professor Sarah Robertson for appraising my work with a level of professionalism I have come to be envious of, and to Professor Rob Norman for support and for giving me the opportunity to undertake this project. I also offer my profound thanks to Associate Professor Cristin Print for productive discussions and his patience in teaching me statistics, bioinformatics and far beyond that. I consider it as an honour to work with such talented and dedicated people, each of you has been an inspiration.

I am indebted to my friends and colleagues at the department that I have had the pleasure of working with. I owe my sincere thanks to Wee Ching Kong for her friendship, moral support and advice on different research aspects; you were always there when I needed you. I would like to express my gratitude to John Schjenken, David Sharkey and Melinda Jasper for teaching me the experimental work and for valuable suggestions regarding my project. I would also like to thank Laura Watson for her willingness to help every time I run into trouble with the Thermocycler, including weekends and after hours. I would like to say a huge thank you to the past and present members of the Endometriosis group for their support and readiness to share ideas, in particular to Maria Teague, Mohammad Zahied Johan, Zhao Wang and Jonathan McGuane.

I would like to acknowledge Dr. Susan Evans and surgical team of the Women's and Children's Hospital for enthusiasm, help in recruitment of patients and collection of the samples. I would also like to recognise Mark van der Hoek and Rosalie Kenyon for their assistance with the microarray experiments and Thomas Sullivan for statistical advice.

I extend my appreciation to Virginia Furness and Kay Govin for all their help with administrative matters. I am grateful to the University of Adelaide and the Robinson institute for my postgraduate scholarship and travel grants.

I offer a sincere thanks to my colleagues at the Women's and Children's Hospital who enabled me to combine the hectic years of research with clinical practice in a new country, particularly to Dr. Geoff Matthews and Associate Professor John Svigos for their tremendous support and

to Dr. Namiko Kobayashi, Dr. Nicole Dryer, Dr Vamsee Thalluri and Dr. Tristan Hardy for their friendship and encouragement.

I take this opportunity to thank Lynnette Zedov, Alex and Natalie Koifman, Nyra and Albert Bensimon, TChow-table mates and many other dear friends of mine for your support, patience and understanding. Thank you for bearing with me, for giving me space and for helping me to get on with life; I am very lucky to have you all.

Lastly, and most importantly, I would like to express my love and gratitude to my dear family, Mum, Dad, Pol, Tal and Michelle, whose unfailing love and support over the years has been beyond measure. Undoubtedly, my husband Pol deserves as much credit for the completion of this thesis as I do. You always stood by me through the good times and bad; without you I would not be where I am today.

PUBLICATIONS ARISING FROM THIS THESIS

Non-invasive tests for the diagnosis of endometriosis. Protocol for the Cochrane review.

Nisenblat V, Farquhar C, Akoum A, Fraser I, Bossuyt PMM, Hull ML.

The Cochrane library, January 2012

Plasma miRNA profiles in women with and without endometriosis – additional considerations towards development of a miRNA-based blood test.

Nisenblat V, Print C, Evans S, Ohlsson-Teague EMC, Robertson S, Hull ML.

Submitted for review, Human Reproduction, January 2013.

Role of miRNAs in endometrial disease in association with reproductive disorders and prospects for circulating miRNAs in diagnosis of endometrial function.

Nisenblat V, Hull ML.

RBM Online, in press 2013.

COMMERCIAL POTENTIAL ARISING FROM THIS THESIS

Patent

Method for identifying endometriosis.

Key contributors: Nisenblat V, Print C, Robertson SA, Ohlsson Teague EMC, Hull ML.

Provisional specification supported by Adelaide Research and Innovation (ARI). Patent filed 20.10.2012

Funding for further work

This thesis served a basis for successful grant application for further work to develop a validated prototype blood test for diagnosis of endometriosis.

Commercial Development Initiative (CDI) fund of \$97,000 + GST was awarded in 2012 by BioInnovation SA (BioSA) to Nisenblat V, Print C, Robertson SA, Hull ML.

ABSTRACTS ARISING FROM THIS THESIS

Menstrual cycle variations in plasma microRNA expression profiles

Ohlsson Teague EMC, Nisenblat V, Robertson SA, Hull ML

Poster presentation. Presented at SRB conference on 23-26.08.2009, Adelaide, Australia.

A unique plasma microRNA expression profile is identified in women with endometriosis

Nisenblat V, Print CG, Evans S, Ohlsson Teague EMC, Robertson SA, Hull ML.

Poster presentation. Presented at the 11th World Congress of Endometriosis on 4-7.09.2011, Montpellier, France.

Plasma miRNAs as non-invasive biomarkers for endometriosis

Nisenblat V, Robertson SA, Evans SF, Hull ML.

Poster presentation. Presented at the ASRM annual meeting on 22-26.10.2012, San Diego, USA.

Circulating microRNAs as potential biomarkers for endometriosis.

Nisenblat V, Wang Z, Robertson SA, Evans SF, Hull ML.

Oral presentation. Presented at Fertility Society of Australia (FSA) conference 28-31.10.12, Auckland, NZ.

LIST OF FIGURES

Figure 1.1 Concordance between the published miRNA profiling studies in endometriosis...	22
Figure 1.2 Molecular events associated with the establishment of endometriotic lesions and the list of the associated miRNAs	23
Figure 1.3 Biogenesis, mechanism of action and extracellular secretion of miRNAs	25
Figure 2.1 The three most commonly used methods for qRT-PCR quantification of miRNAs.	43
Figure 2.2 The structure of LNA monomer and RNA monomer.	43
Figure 2.3 Principles of miRNA microarrays	45
Figure 2.4 MiRNA profiling with next generation sequencing (RNA-seq)	46
Figure 3.1 Optimisation of the RNA extraction – results of RT-PCR performed on the RNA sample extracted from different plasma – Trisol LS ratios.....	67
Figure 3.2 Optimisation of the RNA extraction – results of RT-PCR performed on the RNA samples extracted from diluted and from non-diluted plasma samples.	67
Figure 3.3 Correlation between the input amount of spike-in synthetic miRNAs and PCR results.....	68
Figure 3.4 Relative measures of the 3 spiked-in synthetic templates across various samples.	69
Figure 3.5 Raw and median-normalised Cq values of endogenous miRNA recovered from plasma.....	69
Figure 3.6 Assessment of the intra-operator variability of plasma RNA extraction	71
Figure 3.7 Kinetics of RT reaction	73
Figure 3.8 Kinetics of PCR reaction	73
Figure 3.9 Flow chart for STARD (Standards for reporting diagnostic accuracy) checklist.	91
Figure 4.1 Variability measures of the data, comparison between normalisation approaches.....	100

Figure 4.2 Venn diagram representing a comparison between lists of differentially expressed miRNAs in endometriosis, according to the phase of menstrual cycle.....	104
Figure 4.3 Heat map analysis representing the top ranked plasma miRNAs dysregulated in endometriosis.....	106
Figure 4.4 Comparison of the differentially expressed plasma miRNAs in endometriosis with previously published data on miRNA profile in endometrial tissue (eutopic and ectopic endometrium).....	107
Figure 4.5 Validation of the TLDA data with individual qRT-PCR assays.....	109
Figure 4.6 Ingenuity Pathways Analysis of the 3144 predicted targets of endometriosis-associated circulating miRNAs.....	111
Figure 4.7 Plasma miRNA interactions with endometriosis associated mRNAs	112
Figure 5.1 Example of the network enriched with 12 plasma miRNAs dysregulated in endometriosis, identified in IKB, IPA software.....	123
Figure 6.1 The relationship between endometrial miRNA levels measured by qRT-PCR and RIN.....	139
Figure 6.2 Diagnostic plots - exploratory analysis of the microarray data, Quality Control..	141
Figure 6.3 MiRNAs dysregulated in eutopic endometrium in endometriosis demonstrated with 2 different analyses, ANOVA and LIMMA.....	143
Figure 6.4 Heat map analysis - the top ranked endometrial miRNAs dysregulated in endometriosis.....	144
Figure 7.1 Expression levels of the 2 candidate miRNAs stratified by severity of endometriosis and by presence of endometrioma	173
Figure 7.2 ROC analysis using plasma miR-155	177
Figure 7.3 ROC analysis using plasma miR-574-3p.....	177
Figure 7-4 ROC analysis for the combination of plasma miR-155 + miR-574-3p	178

Figure 7.5 ROC analysis of regression model using miR-574-3p, miR-133a, miR-30c to discriminate endometriosis	178
Figure 7.6 ROC analysis of regression model using the combination of clinical parameters (infertility and number of miscarriages) with miR-574-3p, miR-133a, miR-155 and miR-30c to discriminate endometriosis	181

LIST OF TABLES

Table 1-1 Genes aberrantly expressed in endometrium in association with endometriosis...	11
Table 1-2 Comparative appraisal of current diagnostic approaches to endometriosis	15
Table 1-3 Serum and endometrial markers investigated for diagnosis of endometriosis	17
Table 1-4 Global miRNA profiling studies in endometriosis.....	21
Table 1-5 Functional studies of the selected miRNAs in endometriosis	22
Table 2-1 Large-scale miRNA profiling, comparison between the platforms	41
Table 3-1 Measures of inter and intra-experimental variability of miRNA extraction by the modified Trisol LS method used in our experiments.....	71
Table 3-2 Measures to identify the more suitable normalisation approach; assessment a degree of variability of the raw and normalised data	80
Table 3-3 The QUADAS (Quality assessment of the diagnostic accuracy studies) tool.....	92
Table 4-1 Characteristics of the study population	98
Table 4-2 List of the top ranked miRNAs identified across the menstrual cycle in disease-free controls and in women with endometriosis.....	101
Table 4-3 Differentially expressed miRNAs, wide-scale profiling with TLDA, comparisons by the phase of menstrual cycle.....	103
Table 6-1 Laboratory characteristics of the samples.....	138
Table 6-2 Characteristics of the study population	140
Table 6-3 Dysregulated miRNAs in eutopic endometrium in endometriosis (n = 5) vs. overall disease-free controls (n = 8)	142
Table 6-4 Dysregulated miRNAs in eutopic endometrium in endometriosis (n = 5) vs. symptomatic controls (n = 4).....	145
Table 6-5 Dysregulated miRNAs in eutopic endometrium in endometriosis (n = 5) vs. asymptomatic controls (n = 4)	146

Table 6-6 Dysregulated miRNAs in eutopic endometrium in asymptomatic (n = 4) vs. symptomatic controls (n = 4)	147
Table 7-1 Dysregulated miRNAs in plasma in endometriosis, study phase I	160
Table 7-2 General characteristics of the study population	162
Table 7-3 Clinical characteristics of the study population.....	163
Table 7-4 miRNA expression in plasma in endometriosis (n = 10) and in disease-free women (n = 10), study phase II.....	167
Table 7-5 miRNA expression in plasma set by severity of endometriosis, study phase II	168
Table 7-6 Summary of the candidate miRNAs selected in the study phase II for further validation	169
Table 7-7 Expression of the 8 candidate miRNAs in women with endometriosis (n = 49) and in disease-free controls (n = 19), study phase III.....	170
Table 7-8 Expression of the 8 candidate miRNAs set by severity of endometriosis, study phase III.....	172
Table 7-9 Univariate logistic regression model for association of clinical parameters with endometriosis	179
Table 7-10 Comparison of predictive models for endometriosis identified with multivariate logistic regression analyses.....	180

“...I'm just a normal woman except that I have a horrifying disease called endometriosis. Every month my cycles seem to get worse, making work difficult. I don't enjoy calling in sick and being perceived as being unreliable. I suffer from migraines daily, along with fatigue and pelvis/ back pains ... and I never feel well. I feel like its one thing after another and I'm tired of seeing so many doctors. I'm taking 8 pills a night and I'm only 19. When does it end!!! This has to be one of the most frustrating conditions in the world. Peoples reaction seems to be suck it up, it won't kill you be thankful for that. But what kind of life is this?” Sarah

“... It took me 3 years for a doctor to finally listen to me. I begged doctors to listen to my symptoms....they all assumed I just wanted the pain-relief pills. I hate depending on anything. I can't do the hormones anymore. I want my life back...” Hannah

“My family doesn't quite understand and I've lost almost all of my friends due to the fact that I can't stay out for longer than a couple of hours without feeling drained and ill. My boyfriend of 3 years thinks that I use it as an excuse to not be more active and it's starting to tear us apart. I don't know what to do and I feel completely alone and hopeless at this point. I've lost all hope in the chance that I'll become better ...” Fiona

“... The pain has made me jealous of so many things. Jealous of people who don't have pain, jealous of people who have been able to easily start families, jealous of people who have never known what it feels like to have to make the choices I do. Like should I go out tonight or stay home? Should I take these pain killers and feel better but damage my insides even more? Should I eat this now and feel like crap for days after? Sometimes I think jealousy is the worst side effect of this disorder”. Tracey

(Quotations taken from women diagnosed with endometriosis, 2010-2012)

ABBREVIATIONS

3'-UTR	3'-untranslated regions
AE	amplification efficiency
Ago	argonaute proteins
AID	activation-induced cytidine deaminase
AML	acute myeloid leukaemia
ANOVA	analysis of variance
Anti -2HSG	2 Heremans-Schmidt glycoprotein
ANXA 1	annexin 1
AUC	area under the ROC curve
Bax	BCL2-associated X protein
BCL-2	B-cell lymphoma protein2
B-H	Benjamini-Hochberg method
Bic	B cell integration cluster gene
C. Elegans	Caenorhabditis elegans
Ca-125	cancer antigen 125
CASP	caspase, apoptosis related cysteine peptidase
CCND1	cyclin D1
CDC42	targets cell division cycle 42 protein
CDKN	cyclin-dependent kinase inhibitor
cDNA	complementary DNA
cEBP	CCAAT enhancer binding protein
CK1a	Cysteine kinase 1 alpha
CLL	chronic lymphocytic leukaemia
cMaf	musculoaponeurotic fibrosarcoma oncogene homolog
COL	collagen-matrix proteins
COX	cyclooxygenase
Cq	quantification cycle
CREBBP	CREB binding protein
Ct	cycles to threshold
CTNNB1	β -catenin
CV	coefficient of variance
CXCL	chemokine (C-X-C motif) ligand
CYP19A1	cytochrome P450, family 19, subfamily A, polypeptide
CYR61	cysteine-rich, heparin-binding protein
DNA	deoxyribonucleic acid
DNMT	DNA-(cytosine-5-methyltransferase
DUSP5	dual specificity phosphatase 5
E2	oestradiol
E2F8	E2F transcription factor 8
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
ER	oestrogen receptor
ERBB	v-erb-erythroblastic leukaemia viral oncogene homolog
ERK	extracellular signal-regulated kinase
ESCs	endometrial stromal cells
FADD	Fas associated death domain protein
FC	fold change
FDR	false discovery rate
FGF	fibroblast growth factor
FOXO3	fork head box O3 gene

FSH	follicle-stimulating hormone
GBM	glioblastoma multiforme
GBS	glial cells missing binding site
GEO	gene expression omnibus
GM-CSF	granulocyte macrophage colony-stimulating factor
GNRH	gonadotropin-releasing hormone
HCC	hepatocellular carcinoma
HDL	high-density lipoprotein
HESF	human endometrial stromal fibroblasts
HGF	hepatocyte growth factor
HIF-1 α	hypoxia inducible transcription factor -1 alpha
HLA	human leukocyte antigen
ICAM	intercellular adhesion molecule
IFN	interferon
IGF	insulin-like growth factor
IgG	immunoglobulin G
IKB	ingenuity knowledge base
IKKB	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
IKK ϵ	I κ B kinase epsilon
IL	interleukin
ILGF	insulin-like growth factor
INF	Interferon
IPA	ingenuity systems pathway analysis
IRS-1	insulin receptor substrate-1
JNK	c-Jun N-terminal kinase
KRAS	Kirsten ras oncogene homolog
LDL	low density lipoprotein
LH	luteinizing hormone
LIF	leukaemia inhibitory factor
LIMMA	linear models for microarray analysis
LNA	locked nucleic acid
LOWESS	locally weighted regression and smoothing scatterplots
LPS	Lipopolysaccharide
MAPK	mitogen-activated protein kinase
MAQC	microarray quality control
MCAP	monocyte chemoattractant protein
MCL1	myeloid leukaemia cell differentiation protein
MESDC1	mesoderm development candidate 1
MET- proto-oncogene	MNNG HOS Transforming gene
MGMT	methyl guanine methyl transferase
MIF	migration inhibitory factor
MIP	macrophage inflammatory protein
MIP	macrophage inflammatory protein
MIQE	minimum information for publication of qRT-PCR experiments
miRNA	micro RNA
MMP	matrix metalloproteinase
MRI	magnetic resonance imaging
mRNA	messenger ribonucleic acid
MSC	mesenchymal stem cells
MSH	melanocyte-stimulating hormone
MSP	miRNAs-specific reverse transcription primer
MTMMP	membrane type matrix metalloproteinase
MVB	multivesicular bodies

NFkB	nuclear factor kappaB
ng	nanograms
NK cells	natural killer cells
NP1	nucleoplasmin 1
NPM1	nucleophosmin
NRT	no reverse transcriptase
nSMase2	sphingomyelinase 2
NTC	no template controls
OD	optical density
P4	Progesterone
PAE	percentile amplification efficiency
PAGE	polyacrylamide gel electrophoresis
PCA	principal components analysis
PCOS	polycystic ovary syndrome
PCR	polymerase chain reaction
PDGF	platelet-derived growth factor
PG	prostaglandin
pg	picograms
PGP 9.5	protein gene product 9.5
PP14	serum placental protein/ glycodelin A
PPAR α	peroxisome proliferator-activated receptor, alpha
PR	progesterone receptor
pre-miRNA	precursor miRNA
pri-miRNA	primary miRNA
PRL-3	phosphatase regenerating liver-3 gene
PTEN	phosphatase and tensin homolog
qRT-PCR	quantitative reverse transcriptase PCR
QUADAS	quality assessment of diagnostic accuracy studies included in systematic reviews
r_s	Spearman correlation coefficient
rASRM	revised American Society of Reproductive Medicine classification
REST	RE1-silencing transcription factor
RHOA	Ras homolog gene family, member A
RIN	RNA integrity number
RIPK1	receptor interacting serine–threonine kinase1
RISC	RNA-induced silencing complex
RNA	ribonucleic acid
ROC	receiver-operating characteristics
RQI	RNA quality index
RXR α	retinoid X receptor, alpha
SD	standard deviation
sEcadherin	soluble E-cadherin
SEM	standard error of mean
sEselectin	soluble E-selectin
SF	steroidogenetic factor
SHIP-1	Src homology 2-containing inositol phosphatase-1
sICAM	soluble intercellular adhesion molecules
SMAD	Sma- and Mad-related protein
SMRT	single-molecule real-time sequencing
SMS	single-molecule sequencing
SNR	signal-to-noise ratio
SOCS	suppression of suppressor of cytokine signalling
Sox17	sex determining region Y-related HMG box-17

SQSTM1	Sequestome1 gene
StAR	steroidogenic acute regulatory protein
STARD	standards for reporting of diagnostic accuracy
STAT	signal transducer and activator of transcription
sVCAM	soluble vascular cell adhesion molecule
TCF4	transcription factor 4
TCL1	T cell leukaemia/lymphoma 1
TDP-43	TAR-DNA-binding protein-43
TGF	transforming growth factor
Th	T helper cells
TIMP	tissue inhibitors of MMP
TLDA	TaqMan Low Density miRNA array
TLR	Toll-like receptor
TNF	tumour necrosis factor
TP-53	tumour protein p-53
TP-53INP1	TP-53-induced nuclear protein 1
TR4 [NR2C2]	nuclear receptor subfamily 2 group C member 2
TSP-1	thrombospondin 1 angiogenic protein
UPS	ubiquitin proteasome system
US	ultrasound
VEGF	vascular endothelial growth factor
VENTX	VENT homeobox
VIP	vasoactive intestinal peptide
VSN	variance stabilizing normalization
XIAP	X-linked inhibitor of apoptosis protein
ZFP36	zinc finger protein 36